**Supplemental file Table 6.** Length of hospital stay in total (bed days), and how many of these days were in the intensive care unit (ICU), shown as days post idarucizumab (median, IQR). Thrombotic events, n (%) and mortality, n (%) at 5, 30 and 90 days post idarucizumab are also shown.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Hospital Stay (days)** | **Thrombosis** | **Mortality** |
| **ICU** | **Bed-days** | **0-5** | **0-30** | **0-90** | **0-5** | **0-30** | **0-90** |
| Abdominal n=49 | 2.0 | 9.0(4.0, 16.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (8.2) | 5 (10.2) | 7 (14.3) |
| Orthopedic n=45 | 2.5 | 15.0(8.0-25.0) | 2 (4.4) | 3 (6.7) | 4 (8.9) | 0 (0.0) | 3 (6.7) | 5 (11.1) |
| Vascular n=34 | 4.0 | 9.5(1.0,10.0) | 2 (5.9) | 3 (8.8) | 5 (14.7) | 2 (5.9) | 2 (5.9) | 3 (8.8) |
| Neurosurgery n=8 | 8.0 | 19.0(13.5-51.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 1 (12.5) |
| Gynecology-Urology, n=4 | 0 | 4.0(1.8, 10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Catheter n=29 | 5.0 | 6.5(4.0, 17.0) | 0 (0.0) | 2 (6.9) | 2 (6.9) | 6 (20.7) | 10 (34.5) | 14 (48.3) |
| Drainage, n=20 | 7.0 | 9.0(6.5, 20.0) | 1 (5.0) | 2 (10.0) | 2 (10.0) | 1 (5.0) | 1 (5.0) | 3 (15.0) |
| Diagnostic n=8 | 2.0 | 7.0(3.5, 7.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 1 (12.5) | 2 (25.0) |
| No surgeryn=5 | - | 5.0(4.0, 13.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) | 2 (40.0) | 2 (40.0) |
| **Total n=202** |  |  | **5 (2.5)** | **10(5.0)** | **13 (6.4)** | **16 (7.9)** | **25 (12.4)** | **37 (18.3)** |

**Supplemental file Table 7.** The resumption of antithrombotic treatment in patients after their surgery or procedure (calculated as time from recorded end of procedure to time of anticoagulation initiation). \*Total includes all patients receiving some form of antithrombotic therapy, in many cases this includes more than one agent.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | UFH and/or LMWH | VKA and all NOACs | ASA and/or Clopidogrel | Total\* |
| N (%) | Hours, median (IQR) | N (%) | Days, median (IQR) | dabigatran re-initiated N (%) | N (%) | Days median (IQR) | N (%) |
| Abdominal n=49 | 36(73.5) | 20 (7, 40) | 38(77.6) | 8 (3, 15) | 35 (92.1) | 5 (10.2) | 2 (1, 5) | 44 (89.8) |
| Orthopedic n=45 | 32 (71.1) | 36 (22, 82) | 40 (88.9) | 9 (2, 18) | 36 (90.0) | 12 (26.7) | 4(1, 11) | 45 (100.0) |
| Vascular n=34 | 20 (58.8) | 25 (5-52) | 25 (73.5) | 4 (2, 7) | 21 (84.0) | 9 (26.5) | 1 (1, 5) | 30 (88.2) |
| Neurosurgery n=8 | 4 (50.0) | 279 (107, 511) | 2 (25.0) | 42 (33, 51) | 1(50.0) | 1 (12.5) | 32 (32,32) | 5 (62.5) |
| Gynecology-Urology, n=4 | 3 (75.0) | 25 (8-268) | 4(100.0) | 11 (5-15) | 4 (100.0) | 0 | N/A | 4 (100.0) |
| Catheter n=29 | 14 (48.3) | 56 (23, 137) | 15 (51.7) | 7 (5, 9) | 10 (66.7) | 3 (10.3) | 11 (1, 43) | 22 (75.9) |
| Drainage, n=20 | 16 (80.0) | 27 (20, 58) | 12 (60.0) | 6 (3, 9) | 10 (83.3) | 3 (15.0) | 9(5, 67) | 19 (95.0) |
| Diagnostic n=8 | 5 (62.5) | 22 (16, 31) | 6 (75.0) | 3 (2, 4) | 5 (83.3) | 1 (12.5) | 0.2 (0.2, 0.2) | 7 (87.5) |
| No surgeryn=5 | 2 (40.0) | N/A | 2 (40.0) | 12 (8-17) | 2 (100.0) | 0 | N/A | 3(60.0) |

UFH = Unfractionated heparin, LMWH= Low-Molecular-Weight Heparin, VKA= Vitamin K antagonist, NOAC= Non vitamin K dependent oral anticoagulant, ASA=acetylsalicylic acid, IQR=Interquartile Range.